Bold Therapeutics Presents Late-Breaking Data on BOLD-100's Mitigation of OIPN

Bold Therapeutics Inc., a clinical-stage biopharmaceutical company based in Vancouver, BC, has announced a significant development in oncology treatment. The company's Senior Director of Preclinical Development, Dr. Mark Bazett, is set to present groundbreaking research at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentation will highlight the neuroprotective capabilities of BOLD-100, a clinical-stage anticancer drug, in combating the side effects of chemotherapy.

Scheduled for April 30, 2025, Dr. Bazett, along with Jim Pankovich, EVP of Clinical Development, and Dr. Ashish Kumar, Senior Scientist, will discuss their findings that demonstrate BOLD-100's protective effects against oxaliplatin-induced peripheral neuropathy (OIPN). This discovery is particularly crucial as OIPN is a severe side effect of oxaliplatin, the standard chemotherapy drug for metastatic colorectal cancer (mCRC). With up to 85% of treated patients experiencing neuropathy, the condition often leads to significant pain, tingling, and numbness, severely affecting patients' quality of life and potentially leading to treatment discontinuation.

The research presented by Bold Therapeutics builds on their Phase 2 clinical data, which showcased not only the anticancer efficacy of BOLD-100 but also its ability to drastically reduce the incidence and severity of OIPN. These promising results are paving the way for a Phase 3 clinical trial. The trial is expected to accelerate approval pathways for BOLD-100 in first-line mCRC treatment, potentially benefiting up to 85% of these patients. An independent analysis by a major U.S. life sciences investment bank has projected a multibillion-dollar commercial opportunity for BOLD-100 by 2030, highlighting its significant market potential and the pressing medical needs it addresses.

Peripheral neuropathy, as caused by oxaliplatin, often necessitates dose reductions or treatment cessation, negatively impacting therapeutic outcomes. Currently, there are no approved treatments specifically for preventing or reversing OIPN, forcing oncologists to make tough decisions between maintaining treatment effectiveness and preserving patients' quality of life. Consequently, some physicians opt for alternative therapies such as FOLFIRI, despite their lower efficacy compared to FOLFOX regimens.

BOLD-100's unique ability to enhance the anticancer outcomes of FOLFOX while simultaneously alleviating OIPN symptoms marks a major advancement in cancer therapy. It enables patients to complete their treatment cycles without dose alterations, maintain better functional independence by minimizing pain and sensory issues, and prevent irreversible nerve damage. This improvement in treatment adherence and clinical outcomes could ensure patients fully benefit from first-line chemotherapy regimens.

Currently, Bold Therapeutics is enrolling patients for a multinational randomized clinical study to further evaluate the efficacy, safety, and quality-of-life benefits of FOLFOX with and without BOLD-100 in second-line mCRC patients. The company is optimistic that the trial will further establish BOLD-100 as a transformative therapy for early-line colorectal cancer, biliary tract cancer, and other solid tumor types.

Bold Therapeutics is inviting investors, strategic partners, clinical investigators, and key opinion leaders to engage with their team at the AACR meeting to explore these promising findings, ongoing clinical development, and future collaborative opportunities.

Bold Therapeutics Inc. continues to push the frontiers in oncology with its first-in-class GRP78 inhibitor, BOLD-100, which induces stress-related cancer cell death. The company's innovative approach and promising clinical potential are being actively explored across multiple cancer indications.